A seasoned biologics industry veteran with over 40 years experience turning top-heavy, inefficient operations into profitable facilities; Anthony Rotunno guided Marathon Biopharmaceuticals, once a subsidiary of Boston University, from high net losses to facilities capable of developing multiple generations of biologics. As a result, Marathon became the target in 4 profitable acquisitions and the creation of operations sustaining 300 FT employees and generating $100 million in revenue. Anthony Rotunno was instrumental in recreating Dendreon’s Provenge operations; including the startup, commissioning and validation of 2 new facilities & reducing COGS by approx. 80% over a 5-year period.

A strong Leader & Operational Strategist committed to achieving excellence in all areas of operations and facility management. David has over 25 years of manufacturing experience; covering everything from design to commercialization of manufacturing sites and product approval. David has played a key role in multiple start-ups, including Shire HGT, Dendreon and Vineti. He is well versed in multiple manufacturing platforms including Biologics, API, Small Molecule, Medical Devices, Cellular Immunotherapies and Gene Therapies. David has a strong track record of improving manufacturing operations, operating within budget, and reducing operational costs per unit; while still operating within the highest quality and compliant standards.

David Dautel is a finance and accounting manager and troubleshooter with over 35 years of experience in the field. His expertise lies in analyzing accounting policies and procedures, coordinating accounting personnel, month and year-end close, reconciliations, forecasting, and consolidations. David's focus is on cutting costs, cash management, and internal controls in the pharmaceutical, manufacturing, service, and non-profit-sectors. David Dautel worked closely with Anthony Rotunno and David Vargas in the Provenge Manufacturing turnaround for Dendreon. In addition, David has played an integral role in several successful start-ups.

A seasoned Quality veteran with over 35 years in the pharmaceutical industry and over 10 years within Contract Manufacturing. Tony has a vast array of industry experience including; Biologics, Biopharmaceuticals, Cell Therapy and Medical Devices. He has spent over 10 years helping companies under regulatory stress. Throughout his career Tony has worked with over 15 different FDA offices and dealt with a minimum 10 international regulatory agencies. Tony is strong believer and supporter of the "Team Approach" and shares a strong passion for the work we do!

An exceptional and focused leader with nearly 30 years of operational leadership experience within the Technical Operations divisions of GMP regulated industry. Successfully developed and managed critical production, development and support teams including engineering, metrology, facilities, validation, operations, EH&S and quality systems. Beginning his career in electronics engineering as a decorated Marine, Matt worked as a senior field service engineer before becoming the founder of his first company providing Metrology and Asset Management Services to regulated industry. Matt then turned his focus to building out and managing a Commercial/Clinical pharmaceutical manufacturing facilities for the Biotech, Medical Device, and Pharmaceutical Industries. He possesses extensive team building and project management experience and has led dedicated teams within companies which include PharmaForce, Boston Scientific, Aderans, Dendreon, and Biotest.

John has both a depth and breadth of Life Sciences experience including a combination of Consultative Selling, Business Development, Solution Development, and Account Management. He completed his MBA in Pharmaceutical Business from the University of the Sciences in Philadelphia, PA. For over 20 years he has been applying leading technology for Global PharmaBio and Med Device clients, which includes fourteen years with EMC Documentum. At EMC he was responsible for the Life Sciences Global Industries Group and Global Account Management. John is a proven contributor in the role of defining and implementing Global Strategies with a passion for the Cell and Gene Therapy (CGT) market over the past three years. It is clear that the CGT opportunities require a coordinated view and integrated deployment of Patient Engagement, Scheduling, and Manufacturing. John is devoted to meeting the Immunotherapy and CGT challenges of today by establishing partnerships, continuing to leverage technology, and helping to save lives.